Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2216 • ACR Convergence 2022
JAK Inhibitors and Risk of Cancer
Amandine Gouverneur¹, Jérôme Avouac², Clément Prati³, Jean-Luc Cracowski⁴, Thierry schaeverbeke⁵, Antoine Pariente¹ and Marie-Elise Truchetet⁵, ¹Université de Bordeaux, Bordeaux, France, ²University of Paris, Paris, France, ³Service de rhumatologie, CHU de Besançon, Besançon, France, ⁴Université de Grenoble, Grenoble, France, ⁵CHU de Bordeaux, Bordeaux, France
Background/Purpose: Recent concerns have been raised about potential increase of cancer risk under JAK inhibitors (JAKi) especially tofacitinib. Discrepant findings have been given by randomized…
Abstract Number: PP15 • ACR Convergence 2022
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
Laura Genoves, Arthritis Foundation, Bainbridge Island, WA
Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
Abstract Number: 0021 • ACR Convergence 2022
DB-2306, a Novel Anti-TNFα Monoclonal Antibody Drug Conjugate, Is a Promising Novel Therapeutic Approach for Autoimmune Disease
Xi Li, Yu Zhang, Bing Li and Haiqing Hua, Duality Biologics, Shanghai, China
Background/Purpose: Small molecule immune modulators, such as glucocorticoids (GCs), are highly effective in treatment for various inflammatory diseases. However, prolonged systemic administration of GCs is…
Abstract Number: 0079 • ACR Convergence 2022
Treatment Persistence in First-Line Biologic and Targeted Synthetic DMARD Users with Dual-Seropositive RA in the Medicare Population
Jeffrey Sparks¹, Hanke Zheng², Taylor Schwartz³, Sang Hee Park², Kris Norris³, Vardhaman Patel⁴, Scott Robinson³, Keith Wittstock⁴, Vadim Khaychuk⁵ and Alison Silverstein³, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Bristol Myers Squibb, Princeton, NJ, ³Inovalon Insights, Bowie, MD, ⁴Bristol Myers Squibb, Lawrence Township, NJ, ⁵Bristol Myers Squibb, Pennington, MA
Background/Purpose: The objective of this study was to compare persistence among first-line (1L) abatacept, TNF inhibitors (TNFi), and Janus kinase inhibitors (JAKi) in patients with…
Abstract Number: 0198 • ACR Convergence 2022
Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis
Savia de Souza¹, Andrew Bassett², Ruth Williams² and Elena Nikiphorou³, ¹Independent, London, United Kingdom, ²King's College London, London, United Kingdom, ³Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have relatively recently been licensed to treat inflammatory arthritis (IA); specifically rheumatoid arthritis (RA) and psoriatic arthritis (PsA). They differ…
Abstract Number: 0250 • ACR Convergence 2022
Performance of Fear Assessment in Inflammatory Rheumatic Diseases (FAIR) Questionnaire in a Cohort of Rheumatoid Arthritis Patients in Argentina
Jose Simon Alcivar-Navarrete¹, Joan Manuel Dapeña¹, Juan Manuel Bande¹, Eliana Rebeca Serrano¹, Maria Alejandra Medina¹, Diana Silvia Klajn¹, Jose Angel Caracciolo¹, Analia Dellepiane², Maria Paula Kohan³, Maria Julia Sosa³, maria de los angeles correa⁴, Maximiliano Machado Escobar⁵, Maria Silvia Yacuzzi⁵, Debora Guaglianone⁶, Mariana Benegas⁷, Emel de Jesus Gonzalez Lobato⁸, Eduardo Kerzberg⁸, Sandra Petruzzeli⁹, Beverly De la Puente Perez¹⁰ and Silvia Beatriz Papasidero¹, ¹Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina, ²Centro de Especialidades Medicas Caseros, Casilda, Argentina, ³Hospital Dr. Raul F. Larcade, San Miguel, Buenos Aires, Argentina, ⁴Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Hospital Eva Peron, Banda del Rio Sali, Argentina, ⁶Hospital Provincial de Rosario, Rosario, Santa Fe, Argentina, ⁷Sanatorio Dr. Julio Mendez, Buenos Aires, Argentina, ⁸Hospital General de Agudos Dr. Ramos Mejia, Buenos Aires, Argentina, ⁹Casa Hospital San Juan de Dios, Ramos Mejia, Buenos Aires, Argentina, ¹⁰Hospital General de Agudos Dr. Jose Maria Penna, Buenos Aires, Argentina
Background/Purpose: RA is a systemic disease that can compromise many aspects of patient health. The increased psychological burden of RA is known and multifactorial, recent…
Abstract Number: 0266 • ACR Convergence 2022
Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression
Judith Heutz¹, Cleo Rogier², Ellis Niemantsverdriet³, Susan van den Eeden⁴, Pascal de Jong⁵, Annemieke Geluk⁶ and Annette van der Helm-van Mil⁷, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Erasmus MC, Rotterdam, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁵ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁶Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, ⁷Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Autoantibody responses rise years before onset of inflammatory arthritis (IA) and are stable during transitioning from clinically suspect arthralgia (CSA) to IA (1). Cytokine…
Abstract Number: 0284 • ACR Convergence 2022
Compared Mortality and Cardiovascular Safety of JAK Inhibitors and Tocilizumab in Patients with RA : A Systematic Review and Network Meta-analysis
Daniela Chicre¹, Alisson Pugliesi¹, Manoel Barros Bértolo¹, Vani de Abreu Souza Filho¹ and Luiz Sérgio F Carvalho², ¹Universidade Estadual de Campinas, Campinas, São Paulo, Brazil, ²Clarity: Inteligência em Saúde, Brasília, Brazil
Background/Purpose: The ORAL-Surveillance trial showed important data on the comparative safety between Tofacitinib and TNF inhibitors (TNFi) in the treatment of RA, leading to safety…
Abstract Number: 0300 • ACR Convergence 2022
Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
Yuli Qian¹, Fang Cai², Thierry Sornasse³, Jie Shen¹, Heidi Camp⁴ and Mohamed-Eslam Mohamed¹, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Redwood City, CA, ³AbbVie, South San Francisco, CA, ⁴Abbvie, Winnetka, IL
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of moderately-to-severely active rheumatoid arthritis (RA). Previous investigations demonstrated UPA modulates…
Abstract Number: 0498 • ACR Convergence 2022
A Longitudinal Assessment of Citrulline-specific CD4 T Cells in CCP+ at Risk Subjects and Patients with New-onset Rheumatoid Arthritis
Jing Song¹, Scott Presnell¹, Cliff Rims², Matthew Dufort¹, Hannah DeBerg¹, Peter Linsley², V. Michael Holers³, Kevin D Deane⁴, Eddie James¹ and Jane Buckner¹, ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³University of Colorado, Denver, CO, ⁴University of Colorado Denver Anschutz Medical Campus, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease, in which autoantibodies targeting citrullinated (cit) peptides can be detected prior to diagnosis. We previously reported an…
Abstract Number: 0564 • ACR Convergence 2022
Identifying Shared Genetic Architecture Between RA and Other Conditions: A Phenome-Wide Association Study
Harrison Zhang¹, Gregory McDermott², Thany Seyok², Sicong Huang², Kumar Dahal², Sehi L'Yi¹, Clara Lea-Bonzel¹, Jacklyn Stratton², Dana Weisenfeld², Tianrun Cai², Paul Monach³, Jing Cui², Chuan Hong⁴, Tianxi Cai⁵ and Katherine Liao², ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³VA Boston Healthcare System, Boston, MA, ⁴Duke University, Durham, NC, ⁵Harvard TH Chan School of Public Health, Boston, MA
Background/Purpose: RA shares individual risk alleles with other autoimmune conditions such as type 1 diabetes and celiac disease. However, there are limited studies examining the…
Abstract Number: 0598 • ACR Convergence 2022
An Arthritogenic Strain of Subdoligranulum Specifically Detectable in the Feces of Individuals At-risk for and with Rheumatoid Arthritis Is Bound by ACPA and Stimulates Th17 Cell Activation in Those with Rheumatoid Arthritis
Meagan Chriswell¹, Cliff Rims², Megan Maerz², Alex Hsu³, Jennifer Seifert⁴, Marie Feser⁵, Michelle Bloom³, Elizabeth Bemis⁶, Kristen Demoruelle⁵, Kevin D Deane⁷, William Robinson⁸, Eddie James⁹, Jane Buckner⁹, V. Michael Holers¹⁰ and Kristi Kuhn⁵, ¹UC Denver SOM, Aurora, CO, ²Benaroya Research Institute, Seattle, WA, ³Stanford University, Stanford, CA, ⁴University of Colorado, Littleton, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO, ⁸Stanford University School of Medicine, Palo Alto, CA, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰University of Colorado, Denver, CO
Background/Purpose: We previously demonstrated that intestinal bacteria within the families Lachnospiraceae and Ruminococcaceae are preferentially targeted by ACPA-reactive plasmablast-derived monoclonal antibodies (PB-mAbs) from dual IgA/IgG…
Abstract Number: 0616 • ACR Convergence 2022
Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes
Liam O'Neil¹, XIAOBO MENG¹, Caitin McFadyen¹, Marvin Fritzler² and Hani El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: The detection of anti-citrullinated protein antibodies (ACPA) is associated with increased risk for development of future Rheumatoid Arthritis (RA). The biological events that underpin…
Abstract Number: 0714 • ACR Convergence 2022
Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Serostatus may be associated with different responses to treatment with biologic disease-modifying anti-rheumatic drugs (DMARD) or Janus kinase inhibitors (JAKi) in patients with rheumatoid…
Abstract Number: 0775 • ACR Convergence 2022
The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment
Tam Quach¹, Meggan Mackay², Cynthia Aranow² and Anne Davidson², ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: The development of new autoantibodies and secondary autoimmunity is a common and significant side effect of TNF inhibitors (TNFi) which are widely used to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].